Mereo Biosciences is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Lead candidate, setrusumab, is in Phase III development in partnership with Ultragenyx, and other pipeline products, alvelestat and etigilimab, are in Phase II development.